Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at . SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
2024年11月27日，西雅图（全球新闻资讯社）- Perspective Therapeutics, Inc.（"透视"或"公司"）(纽交所美国: CATX)，一家开拓癌症全身治疗领先爱文思控股的放射制药公司，今天宣布其高级领导团队成员将参加并与投资者在以下即将举行的投资者会议上进行一对一会议。
36th Annual Piper Healthcare Conference
Date: December 3, 2024
Location: New York, NY
Format: Fireside Chat
Time: 10:00-10:25 AM ET
第36届Piper医疗保健大会
日期：2024年12月3日
地点：纽约，纽约州
格式：炉边聊天
时间：东部时间上午10:00-10:25
7th Annual Evercore HealthCONx
Date: December 5, 2024
Location: Coral Gables, FL
Format: Fireside Chat
Time: 10:50-11:10 AM ET
第7届Evercore HealthCONx大会
日期：2024年12月5日
地点：佛罗里达科勒尔盖布尔斯
格式：炉边聊天
时间：上午10:50-11:10 ET
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at .
网络研讨会可现场观看，并且重播将存档90天，并通过Perspective网站的投资者页面进行回放。
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
关于 Perspective Therapeutics公司
Perspective Therapeutics Inc.是一家放射性制药公司，致力于开创全身各部位癌症治疗的先进技术。该公司拥有专有技术，利用α放射性同位素212Pb通过专门定位的肽子将强大的辐射能量精确传递到癌细胞。该公司还在开发互补成像诊断方法，这些成像诊断方法包括与相同定位肽相结合，这提供了个性化治疗的机会，并优化患者的治疗效果。这种“诊治一体化”方法能够在看到具体肿瘤并针对性治疗的同时，促进治疗效果的提高、毒性反应的最小化。
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
该公司的黑色素瘤（VMT01）和神经内分泌肿瘤（VMt-α-NET）项目已经进入了几个领先的学术机构的转移性黑色素瘤和神经内分泌肿瘤的第1/2a期成像和治疗试验。该公司还开发了一种专有的212Pb发生器，以确保临床试验和商业运营的关键同位素。
For more information, please visit the Company's website at .
欲了解更多信息，请访问该公司的网站。
CONTACT: Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
联系人：媒体和投资者关系联系人：
Perspective Therapeutics IR：
Annie J. Cheng, 爱文思控股
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
